TY - JOUR
T1 - The role of cytokines in the initiation and progression of myelofibrosis
AU - Hasselbalch, Hans K
N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.
PY - 2013/4
Y1 - 2013/4
N2 - Myelofibrosis (MF) is a life-threatening blood cancer characterized by progressive bone marrow fibrosis, splenomegaly, cytopenias, and debilitating constitutional symptoms. Abnormal expression and activity of a number of proinflammatory cytokines are associated with MF, in which immune dysregulation is pronounced as evidenced by dysregulation of several immune and inflammation genes. The discovery of the Janus kinase 2 (JAK2) V617F mutation has led to the development of a number of JAK1/2 inhibitors in the treatment of MF and similar neoplasms. Here, the role of cytokines in MF initiation and progression is discussed, the impact of current therapies is reviewed, and new combination therapies are proposed, such as JAK1/2 inhibitors with interferons, statins, and epigenetic modifiers for patients with MF and related neoplasms.
AB - Myelofibrosis (MF) is a life-threatening blood cancer characterized by progressive bone marrow fibrosis, splenomegaly, cytopenias, and debilitating constitutional symptoms. Abnormal expression and activity of a number of proinflammatory cytokines are associated with MF, in which immune dysregulation is pronounced as evidenced by dysregulation of several immune and inflammation genes. The discovery of the Janus kinase 2 (JAK2) V617F mutation has led to the development of a number of JAK1/2 inhibitors in the treatment of MF and similar neoplasms. Here, the role of cytokines in MF initiation and progression is discussed, the impact of current therapies is reviewed, and new combination therapies are proposed, such as JAK1/2 inhibitors with interferons, statins, and epigenetic modifiers for patients with MF and related neoplasms.
KW - Animals
KW - Cytokines
KW - Disease Progression
KW - Humans
KW - Janus Kinases
KW - Primary Myelofibrosis
KW - STAT Transcription Factors
U2 - 10.1016/j.cytogfr.2013.01.004
DO - 10.1016/j.cytogfr.2013.01.004
M3 - Journal article
C2 - 23415024
SN - 1359-6101
VL - 24
SP - 133
EP - 145
JO - Cytokine & Growth Factor Reviews
JF - Cytokine & Growth Factor Reviews
IS - 2
ER -
